MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease and atypical parkinsonian syndrome

J. Horie, H. Fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Matsubara, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata (Shimotsuga-gun, Japan)

Meeting: 2017 International Congress

Abstract Number: 1473

Keywords: Substantia nigra

Session Information

Date: Thursday, June 8, 2017

Session Title: Parkinson's Disease: Neuroimaging And Neurophysiology

Session Time: 1:15pm-2:45pm

Location: Exhibit Hall C

Objective: To evaluate whether the hyperechogenic size of the substantia nigra changes with time in Parkinson’s disease (PD) and atypical parkinsonian syndromes (APSs), such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).

Background: Hyperechogenicity of the substantia nigra (SN) in transcranial sonography (TCS) is observed more frequently inpatients with PD compared with patients with APS. Several previous studies showed that the SN hyperechogenisity area did not change during the disease course. However, it remains unclear whether or not the SN hyperechogenic areas change in patients with APS.

Methods: The patients with PD-related disorders who underwent TCS twice (at least 6 months apart) during the disease course were enrolled in this study. Patients with insufficient temporal bone windows were excluded. A total of 20 parkinsonian patients (PD 13, age 69.5±9.6 years; APS 7, age 72.1±7.8 years) were included.

Results:  The mean interval of the examinations was 24.0±14.3 months. No differences were detected between the first and second examination in the SN hyperechogenicity area (total patients, 0.17±0.10 cm2 vs 0.16±0.10 cm2, p=0.53; PD, 0.19±0.11 cm2 vs 0.18±0.12 cm2, p=0.62; APS, 0.13±0.09 cm2 vs 0.12±0.08 cm2, p=0.74, respectively). In both groups, there was no correlation between disease duration, severity and the SN hyperechogenicity area.

Conclusions: SN hyperehogenicity area did not change during the disease course in patients with PD and APS.

To cite this abstract in AMA style:

J. Horie, H. Fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Matsubara, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata. A follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease and atypical parkinsonian syndrome [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/a-follow-up-study-of-hyperechogenicity-of-the-substantia-nigra-in-parkinsons-disease-and-atypical-parkinsonian-syndrome/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-follow-up-study-of-hyperechogenicity-of-the-substantia-nigra-in-parkinsons-disease-and-atypical-parkinsonian-syndrome/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley